Search results for "Dendritic cells."

showing 10 items of 360 documents

Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.

2007

Abstract Genetic modification of vaccines by linking the Ag to lysosomal or endosomal targeting signals has been used to route Ags into MHC class II processing compartments for improvement of CD4+ T cell responses. We report in this study that combining an N-terminal leader peptide with an MHC class I trafficking signal (MITD) attached to the C terminus of the Ag strongly improves the presentation of MHC class I and class II epitopes in human and murine dendritic cells (DCs). Such chimeric fusion proteins display a maturation state-dependent subcellular distribution pattern in immature and mature DCs, mimicking the dynamic trafficking properties of MHC molecules. T cell response analysis in…

CD4-Positive T-LymphocytesT cellRecombinant Fusion ProteinsImmunologyAntigen presentationMolecular Sequence DataMice Inbred StrainsCD8-Positive T-LymphocytesProtein Sorting SignalsMajor histocompatibility complexTransfectionViral Matrix ProteinsEpitopesMiceAntigens NeoplasmMHC class ImedicineImmunology and AllergyAnimalsHumansAmino Acid SequenceAntigensMHC class IIAntigen PresentationbiologyAntigen processingHistocompatibility Antigens Class IVaccinationMembrane ProteinsDendritic CellsMHC restrictionPhosphoproteinsCell biologyProtein Transportmedicine.anatomical_structurebiology.proteinCD8Journal of immunology (Baltimore, Md. : 1950)
researchProduct

Dendritic Cells Lose Ability to Present Protein Antigen after Stimulating Antigen-Specific T Cell Responses, despite Upregulation of MHC Class II Exp…

2000

Abstract Immature dendritic cells (DC) take up, process and present protein antigens; mature DC are specialized for stimulating primary T cell responses with increased expression of MHC class II and co-stimulatory molecules, but are incapable of processing and presenting soluble protein. The current study examined whether maturation of DC is triggered by T cell recognition of antigens presented by immature DC. Human DC derived from CD34+ progenitor cells by culture with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) in serum-free medium could prime naive CD4+ T cells to keyhole limpet hemocyanin (KLH) and ovalbumin (OVA). The cultured DC retained the abil…

CD4-Positive T-LymphocytesTime FactorsOvalbuminT cellImmunologyCD1Bone Marrow CellsCell CommunicationCulture Media Serum-FreeInterferon-gammaInterleukin 21medicineHumansImmunology and AllergyCytotoxic T cellIL-2 receptorCD40 AntigensAntigen-presenting cellCells CulturedAntigen PresentationMHC class IIbiologyInterleukin-6Tumor Necrosis Factor-alphaHistocompatibility Antigens Class IIGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationDendritic CellsHematologyIntercellular Adhesion Molecule-1Natural killer T cellMolecular biologyCoculture Techniquesmedicine.anatomical_structureHemocyaninsB7-1 Antigenbiology.proteinImmunobiology
researchProduct

Allergic contact dermatitis: understanding the immune response and potential for targeted therapy using cytokines.

1997

Allergic contact dermatitis is the most common job-related disease of the western world. The only available treatments are avoidance of contact with the allergen and the use of potent corticosteroids. Recently, the role of cytokines in the pathogenesis of this disease has been studied and, besides defining the key molecules and basic cellular immune responses responsible for disease development, these studies might help to develop new therapeutic strategies to target cytokines and thereby try to alter or abrogate ongoing immune reactions.

CD4-Positive T-Lymphocytesmedicine.medical_treatmentT-LymphocytesDiseaseCD8-Positive T-Lymphocytesmedicine.disease_causeLymphocyte ActivationTargeted therapyPathogenesisMiceImmune systemAllergenGeneticsmedicineAnimalsHumansRNA AntisenseAllergic contact dermatitisbusiness.industryDendritic CellsGenetic Therapymedicine.diseaseLangerhans CellsImmunologyDermatitis Allergic ContactMolecular MedicineCytokinesImmune reactionbusinessMolecular medicine today
researchProduct

A novel plasmid DNA electroporation method allows transfection of murine DC.

2007

Under steady state conditions dendritic cells (DC) exert tolerogenic function, but acquire potent immunogenic function due to strong upregulation of costimulatory molecules and proinflammatory cytokines. In numerous studies the potential of modified DC to induce tolerance or immune reactions towards a distinct antigen has been demonstrated. However, DC are refractory to transfection with plasmid DNA by non-viral methods. In this study we have tested the suitability of a newly developed electroporation device to transfect immature murine bone-marrow derived DC (BM-DC). Transfected BM-DC expressed reporter molecules at considerable extent which renders this method suitable to perform all kind…

CD4-Positive T-LymphocytesvirusesTransgeneT cellImmunologyGenetic VectorsGene ExpressionMice TransgenicBiologyTransfectionProinflammatory cytokineMyelin oligodendrocyte glycoproteinMicemedicineImmunology and AllergyAnimalsTransgenesCells CulturedCell ProliferationMice Inbred BALB CExpression vectorElectroporationTransfectionDendritic cellDendritic CellsMolecular biologyInterleukin-10Mice Inbred C57BLMyelin-Associated Glycoproteinmedicine.anatomical_structureElectroporationbiology.proteinFemaleMyelin-Oligodendrocyte GlycoproteinMyelin ProteinsPlasmidsJournal of immunological methods
researchProduct

Differential expression of alternative H2-M isoforms in B cells, dendritic cells and macrophages by proinflammatory cytokines.

1999

Major histocompatibility (MHC) class II heterodimers bind peptides generated by degradation of endocytosed antigens and display them on the surface of antigen presenting cells (APCs) for recognition by CD4+ T cells. Efficient loading of MHC class II molecules with peptides is catalyzed by the MHC class II-like molecule H2-M. The coordinate regulation of MHC class II and H2-M expression is a prerequisite for efficient MHC class II/peptide assembly in APCs determining both the generation of the T cell repertoire in the thymus and cellular immune responses in the periphery. Here we show that expression of H2-M and MHC class II genes is coordinately and cell type-specific regulated in splenic B…

CD74ImmunologyAntigen presentationGenes MHC Class IICD1Antigen-Presenting CellsGene ExpressionIn Vitro TechniquesMHC Class II GeneMiceMHC class IAnimalsProtein IsoformsMolecular BiologyDNA PrimersMHC class IIB-LymphocytesHLA-D AntigensMice Inbred BALB CbiologyBase SequenceAntigen processingHistocompatibility Antigens Class IIDendritic CellsMHC restrictionMolecular biologybiology.proteinMacrophages PeritonealCytokinesInflammation MediatorsMolecular immunology
researchProduct

β-Catenin Signaling Drives Differentiation and Proinflammatory Function of IRF8-Dependent Dendritic Cells

2014

Abstract β-Catenin signaling has recently been tied to the emergence of tolerogenic dendritic cells (DCs). In this article, we demonstrate a novel role for β-catenin in directing DC subset development through IFN regulatory factor 8 (IRF8) activation. We found that splenic DC precursors express β-catenin, and DCs from mice with CD11c-specific constitutive β-catenin activation upregulated IRF8 through targeting of the Irf8 promoter, leading to in vivo expansion of IRF8-dependent CD8α+, plasmacytoid, and CD103+CD11b− DCs. β-Catenin–stabilized CD8α+ DCs secreted elevated IL-12 upon in vitro microbial stimulation, and pharmacological β-catenin inhibition blocked this response in wild-type cells…

CD8 AntigensCellular differentiationImmunologyReceptors Cell SurfaceVaccinia virusPyrimidinonesCD8-Positive T-LymphocytesBiologyParasite LoadArticleProinflammatory cytokineMiceAntigens CDVacciniaAnimalsImmunology and AllergyPromoter Regions Geneticbeta CateninInflammationMice KnockoutCell DifferentiationDendritic CellsT lymphocyteTh1 CellsBridged Bicyclo Compounds HeterocyclicInterleukin-12CD11c AntigenCell biologyEnzyme ActivationMice Inbred C57BLInterferon Regulatory FactorsInterleukin 12FemaleIRF8Signal transductionIntegrin alpha ChainsToxoplasmaSpleenToxoplasmosisCD8Signal TransductionInterferon regulatory factorsThe Journal of Immunology
researchProduct

Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompati…

2002

To identify endocytic receptors that allow dendritic cells (DCs) to capture and present antigens on major histocompatibility complex (MHC) class I products in vivo, we evaluated DEC-205, which is abundant on DCs in lymphoid tissues. Ovalbumin (OVA) protein, when chemically coupled to monoclonal alphaDEC-205 antibody, was presented by CD11c+ lymph node DCs, but not by CD11c- cells, to OVA-specific, CD4+ and CD8+ T cells. Receptor-mediated presentation was at least 400 times more efficient than unconjugated OVA and, for MHC class I, the DCs had to express transporter of antigenic peptides (TAP) transporters. When alphaDEC-205:OVA was injected subcutaneously, OVA protein was identified over a …

CD8-Positive T-LymphocytesMice0302 clinical medicineImmunology and AllergyCytotoxic T cellMice KnockoutAntigen Presentation0303 health sciencesMembrane GlycoproteinstoleranceAntibodies MonoclonalDEC-205 receptorrespiratory systemFlow CytometryEndocytosismedicine.anatomical_structureMHC class IFemaleOvalbuminT cellImmunologyAntigen presentationReceptors Cell Surfacechemical and pharmacologic phenomenaBiologyMajor histocompatibility complexArticleMinor Histocompatibility Antigens03 medical and health sciencesAntigenAntigens CDMHC class IImmune TolerancemedicineAnimalsLectins C-Typedendritic cellsAntigensCD40 Antigens030304 developmental biologyHistocompatibility Antigens Class IDendritic cellMolecular biologyCD11c AntigenMice Inbred C57BLCD8 T cellbiology.proteinLymph NodesCarrier ProteinsCD8030215 immunologyJournal of Experimental Medicine
researchProduct

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1

2014

Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human immune system. The recent development of new antibodies against immune check points may help to overcome the immune silencing induced by human tumors. Some of these antibodies have already been approved for treatment of various solid tumor entities. Interestingly, targeting antibodies may be combined with standard chemotherapy or radiation protocols. Furthermore, recent evidence indicates that intratumoral (it) or intravenous (iv) injections of replicative oncolytic viruse…

Cancer ResearchParvovirus H-1medicine.medical_treatmentautonomous parvovirusReview Articlelcsh:RC254-282JX-594Immune systemAntigenmedicineDentritic cellsdendritic cellsVirotherapybusiness.industryImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virusH-1PVT-VECtalimogene laherparepvecOncologyCTLA-4ImmunologyCTLA-4immunotherapyTalimogene laherparepvecbusinessFrontiers in Oncology
researchProduct

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.

1997

Escape from immune surveillance is critical for tumor progression in metastatic melanoma. We assessed the function of melanoma-derived dendritic cells (DCs) in patients presenting simultaneously with responding (rM) or progressing (pM) melanoma metastases. These rare coincidences allowed us to compare syngeneically the function of tumor DCs. CD83+ DCs were purified freshly from large responding (rDCs) or progressing (pDCs) metastases following chemo-immunotherapy. rDCs were 5 times more potent inducers of allogeneic T-cell proliferation than the pDCs that were used as control. Phenotypic analysis showed a marked depression of CD86 expression on pDCs. Culture supernatants from pM showed prod…

Cancer ResearchT-LymphocytesImmune toleranceImmune systemAntigens CDAntigens NeoplasmAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntigen-presenting cellMelanomaCD86Membrane Glycoproteinsbusiness.industryMelanomaInterferon-alphahemic and immune systemsDendritic cellDendritic Cellsmedicine.diseaseInterleukin-10Neoplasm ProteinsTolerance inductionOncologyTumor progressionImmunologyCytokinesInterleukin-2Tumor EscapeB7-2 AntigenCisplatinbusinessCell DivisionInternational journal of cancer
researchProduct